IMMUNOVANT ($IMVT) posted quarterly earnings results for Q2 2027 on Monday, November 9th. The company reported earnings of -$0.47 per share, beating estimates of -$0.75 by $0.28. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $IMVT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
IMMUNOVANT Insider Trading Activity
IMMUNOVANT insiders have traded $IMVT stock on the open market 34 times in the past 6 months. Of those trades, 0 have been purchases and 34 have been sales.
Here’s a breakdown of recent trading of $IMVT stock by insiders over the last 6 months:
- ANDREW J. FROMKIN has made 0 purchases and 2 sales selling 221,951 shares for an estimated $7,438,111.
- JAY S STOUT (Chief Technology Officer) has made 0 purchases and 10 sales selling 52,748 shares for an estimated $1,977,987.
- MELANIE GLORIA (Chief Operating Officer) has made 0 purchases and 6 sales selling 25,047 shares for an estimated $965,935.
- TUYL CHRISTOPHER VAN (Chief Legal Officer) has made 0 purchases and 6 sales selling 22,991 shares for an estimated $866,349.
- TIAGO GIRAO (Chief Financial Officer) has made 0 purchases and 3 sales selling 23,404 shares for an estimated $835,885.
- ATUL PANDE has made 0 purchases and 5 sales selling 12,000 shares for an estimated $424,650.
- ERIC VENKER (Chief Executive Officer) has made 0 purchases and 2 sales selling 6,598 shares for an estimated $238,569.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
IMMUNOVANT Hedge Fund Activity
We have seen 109 institutional investors add shares of IMMUNOVANT stock to their portfolio, and 94 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEEP TRACK CAPITAL, LP removed 2,185,820 shares (-19.0%) from their portfolio in Q2 2026, for an estimated $84,219,644
- ARMISTICE CAPITAL, LLC removed 1,828,916 shares (-51.3%) from their portfolio in Q2 2026, for an estimated $70,468,133
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,648,638 shares (+287.5%) to their portfolio in Q2 2026, for an estimated $63,522,022
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,489,603 shares (+438.6%) to their portfolio in Q2 2026, for an estimated $57,394,403
- TWO SEAS CAPITAL LP added 1,464,187 shares (+46.5%) to their portfolio in Q3 2026, for an estimated $49,460,236
- ALPINE GLOBAL MANAGEMENT, LLC removed 1,261,925 shares (-47.9%) from their portfolio in Q2 2026, for an estimated $48,621,970
- D. E. SHAW & CO., INC. added 1,240,654 shares (+inf%) to their portfolio in Q2 2026, for an estimated $47,802,398
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
IMMUNOVANT Price Targets
Multiple analysts have issued price targets for $IMVT recently. We have seen 5 analysts offer price targets for $IMVT in the last 6 months, with a median target of $43.0.
Here are some recent targets:
- Samantha Semenkow from Citigroup set a target price of $61.0 on 06/30/2026
- Yatin Suneja from Guggenheim set a target price of $62.0 on 05/26/2026
- Danielle Brill from Truist Securities set a target price of $30.0 on 05/22/2026
- Douglas Tsao from HC Wainwright & Co. set a target price of $40.0 on 05/21/2026
- Jason Gerberry from B of A Securities set a target price of $43.0 on 05/21/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
